• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23369 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2015     Penn Medicine Center for Evidence-based Practice (CEP) Oral rehydration therapy for adults with acute infectious gastrointestinal disease
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dulaglutide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal). NICE technology appraisal guidance 353
2015     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of foam sclerotherapy, endovenous laser ablation and surgery for varicose veins: results from the CLASS trial
2015     Agency for Healthcare Research and Quality (AHRQ) Systematic review for effectiveness of hyaluronic acid in the treatment of severe degenerative joint disease (DJD) of the knee
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir (Addendum to Commission A14-44)]
2015     National Institute for Health and Care Excellence (NICE) Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism. NICE technology appraisal guidance 354
2015     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination against pertussis: aims and strategy
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Screening for visual impairment in children younger than 6 years - rapid report]
2015     National Institute for Health and Care Excellence (NICE) Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation. NICE technology appraisal guidance 355
2015     Penn Medicine Center for Evidence-based Practice (CEP) Hospitalist clinics for post-discharge care
2015     Health Council of the Netherlands Gezondheidsraad (GR) 4,4'-Methylenedianiline - Health-based calculated occupational cancer risk values
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apremilast - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab. NICE technology appraisal guidance 357
2015     NIHR Health Technology Assessment programme Smoking Cessation Intervention for severe Mental Ill Health Trial (SCIMITAR): a pilot randomised control trial of the clinical effectiveness and cost-effectiveness of a bespoke smoking cessation service
2015     Penn Medicine Center for Evidence-based Practice (CEP) Pre-operative cardiovascular surgery patient education
2015     NIHR Health Technology Assessment programme The clinical effectiveness and cost-effectiveness of open mesh repairs in adults presenting with a clinically diagnosed primary unilateral inguinal hernia who are operated in an elective setting: systematic review and economic evaluation
2015     Health Council of the Netherlands Gezondheidsraad (GR) 1,4-Dioxane - re-evaluation of the carcinogenicity and genotoxicity
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Stents for the treatment of intracranial artery stenosis: VISSIT study and acute treatment in Germany (working paper on commission N14-01)]
2015     National Institute for Health and Care Excellence (NICE) Tolvaptan for treating autosomal dominant polycystic kidney disease. NICE technology appraisal guidance 358
2015     Health Council of the Netherlands Gezondheidsraad (GR) 2,6-Xylidine - re-evaluation of the carcinogenicity and genotoxicity
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nintedanib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Idelalisib for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 359
2015     Health Council of the Netherlands Gezondheidsraad (GR) Methodology for the evaluation of the evidence for the Dutch dietary guidelines 2015 - background document
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Treatment of haemophilia patients - Rapid report]
2015     National Institute for Health and Care Excellence (NICE) Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 362
2015     Penn Medicine Center for Evidence-based Practice (CEP) Inpatient mental health unit décor
2015     Health Council of the Netherlands Gezondheidsraad (GR) Shiftwork and health risks: possibilities for prevention
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Ledipasvir-sofosbuvir for treating chronic hepatitis C. NICE technology appraisal guidance 363
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tafluprost/timolol (Addendum to Commission A14-49)]
2015     National Institute for Health and Care Excellence (NICE) Ombitasvir-paritaprevir-ritonavir with or without dasabuvir for treating chronic hepatitis C. NICE technology appraisal guidance 365
2015     NIHR Health Technology Assessment programme Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review short report
2015     Penn Medicine Center for Evidence-based Practice (CEP) Locking solutions for central venous catheters
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Pembrolizumab for advanced melanoma not previously treated with ipilimumab. NICE technology appraisal guidance 366
2015     NIHR Health Services and Delivery Research programme Tele-First: telephone triage as an alternative to face to face contact in general practice
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Testing of a method for assessing the internal validity of guideline recommendations, using the example of evidence-based guidelines on preoperative diagnostics]
2015     National Institute for Health and Care Excellence (NICE) Vortioxetine for treating major depressive episodes. NICE technology appraisal guidance 367
2015     NIHR Health Technology Assessment programme The relative clinical and cost-effectiveness of three contrasting approaches to partner notification for curable sexually transmitted infections (STIs): a cluster randomised trial in primary care
2015     NIHR Health Services and Delivery Research programme Intentional rounding in hospital wards: What works, for whom and in what circumstances?
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eliglustat - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2015     National Institute for Health and Care Excellence (NICE) Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears. NICE technology appraisal guidance 369
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dasabuvir/ombitasvir/paritaprevir/ritonavir (Addendum to Commissions A15-03 and A15-04)]
2015     National Institute for Health and Care Excellence (NICE) Bortezomib for previously untreated mantle cell lymphoma. NICE technology appraisal guidance 370
2015     NIHR Health Technology Assessment programme Clinical diagnostic accuracy of rapid detection of healthcare-associated bloodstream infection in critical care using multi-pathogen real-time polymerase chain reaction (RT-PCR) technology
2015     NIHR Horizon Scanning Centre (NIHR HSC) Lonsurf (trifluridine and tipiracil hydrochloride) for metastatic colorectal cancer – third line
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dulaglutide (Addendum to Commission A15-07)]
2015     National Institute for Health and Care Excellence (NICE) Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis. NICE technology appraisal guidance 373
2015     NIHR Horizon Scanning Centre (NIHR HSC) AZD9291 for locally advanced or metastatic, EGFR and T790M mutation positive non-small cell lung cancer – second line
2015     Institute of Health Economics (IHE) A systematic review of the measurement properties of self-report instruments that assess presenteeism
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     NIHR Health Technology Assessment programme The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study
2015     NIHR Health Services and Delivery Research programme The SHAPE project: Supporting adults with High-functioning Autism and asPerger syndromE. Mapping and evaluating specialist autism team service models
2015     NIHR Horizon Scanning Centre (NIHR HSC) Sodium thiosulfate for prevention of hearing loss in children receiving cisplatin chemotherapy
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ruxolitinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     NIHR Horizon Scanning Centre (NIHR HSC) Ipilimumab (Yervoy) for small cell lung cancer – first line, in combination with etoposide and platinum therapy
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec (addendum to commission A15-10)]
2015     The Swedish Council on Health Technology Assessment (SBU) [Arginine and caries prevention]
2015     NIHR Horizon Scanning Centre (NIHR HSC) Selumetinib for metastatic uveal melanoma – first line
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec/liraglutide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     NIHR Health Services and Delivery Research programme Planning for a cohort study to investigate the impact and management of influenza in pregnancy in a future pandemic
2015     NIHR Horizon Scanning Centre (NIHR HSC) Ibrutinib (Imbruvica) for Waldenström's macroglobulinaemia
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vortioxetine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015     NIHR Health Technology Assessment programme Diagnostic accuracy of the Thessaly test, standardised clinical history and other clinical examination tests (Apley's, McMurray's and joint line tenderness) for meniscal tears in comparison with magnetic resonance imaging diagnosis
2015     NIHR Health Services and Delivery Research programme The value and cost of different forms of information on oral health status and risk given to patients following a check-up in dental practice
2015     NIHR Horizon Scanning Centre (NIHR HSC) Nimotuzumab for advanced pancreatic cancer – second line
2015     Canadian Agency for Drugs and Technologies in Health (CADTH) Public health interventions to reduce the secondary spread of measles
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afatinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     NIHR Health Technology Assessment programme Strengthening And stretching for Rheumatoid Arthritis of the Hand (SARAH). A randomised controlled trial and economic evaluation
2015     NIHR Health Technology Assessment programme The management of Otitis Media with Effusion in children with cleft palate (mOMEnt): a feasibility study and economic evaluation
2015     NIHR Health Technology Assessment programme The PAndemic INfluenza Triage in the Emergency Department (PAINTED) pilot cohort study
2015     Belgian Health Care Knowledge Centre (KCE) Hadron therapy in children – an update of the scientific evidence for 15 paediatric cancers
2015     NIHR Horizon Scanning Centre (NIHR HSC) Evofosfamide for locally advanced, unresectable or metastatic pancreatic cancer – first line in combination with gemcitabine
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Safinamide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     Belgian Health Care Knowledge Centre (KCE) Cervical cancer screening program and Human Papillomavirus (HPV) testing, part II: Update on HPV primary screening
2015     HAYES, Inc. Absorbable perirectal spacer (SpaceOAR System; Augmenix Inc.) during radiation therapy for prostate cancer
2015     NIHR Horizon Scanning Centre (NIHR HSC) Ixekizumab for moderate to severe chronic plaque psoriasis
2015     Canadian Agency for Drugs and Technologies in Health (CADTH) Long-term use of acamprosate calcium for alcoholism: a review of the clinical effectiveness, safety, and guidelines
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015     NIHR Health Technology Assessment programme Clinical effectiveness and cost-effectiveness of parenting interventions for children with severe attachment problems: a systematic review and meta-analysis
2015     Belgian Health Care Knowledge Centre (KCE) Next generation sequencing gene panels for targeted therapy in oncology and haemato-oncology
2015     HAYES, Inc. Adalimumab (humira) for treatment of pediatric Crohn's disease
2015     NIHR Horizon Scanning Centre (NIHR HSC) Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015     NIHR Health Technology Assessment programme Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis
2015     Belgian Health Care Knowledge Centre (KCE) Cardiovascular pre-participation screening in young athletes
2015     HAYES, Inc. Augment bone graft (Wright Medical Group Inc.) for bone regeneration in ankle and/or hindfoot fusions
2015     NIHR Horizon Scanning Centre (NIHR HSC) Masitinib for amyotrophic lateral sclerosis – add-on therapy to riluzole
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     NIHR Health Technology Assessment programme Rapid detection of health-care-associated bloodstream infection in critical care using multipathogen real-time polymerase chain reaction technology: a diagnostic accuracy study and systematic review
2015     Belgian Health Care Knowledge Centre (KCE) Non-invasive markers of subclinical atherosclerosis for predicting a primary cardiovascular event: a rapid systematic review
2015     HAYES, Inc. Eliglustat (Cerdelga) for Gaucher disease type 1
2015     NIHR Horizon Scanning Centre (NIHR HSC) Reslizumab for eosinophilic asthma
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ruxolitinib (Addendum to Commission A15-13)]
2015     NIHR Health Technology Assessment programme Double-blind randomised controlled trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in the treatment of faecal incontinence: CONtrol of Faecal Incontinence using Distal NeuromodulaTion (the CONFIDeNT trial)
2015     NIHR Public Health Research (PHR) programme Preschoolers in the Playground: a pilot cluster randomised controlled trial of a physical activity intervention for children aged 18 months to 4 years
2015     HAYES, Inc. Elosulfase alpha (Vimizim) for treatment of Morquio A Syndrome
2015     NIHR Horizon Scanning Centre (NIHR HSC) Biotin (Cerenday) for primary and secondary progressive multiple sclerosis - first line
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lomitapide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]